Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference
Tenax Therapeutics (Nasdaq: TENX) will participate in a fireside chat at the 2026 Leerink Partners Global Healthcare Conference in Miami, March 8-11, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tenax Therapeutics (Nasdaq: TENX) will participate in a fireside chat at the 2026 Leerink Partners Global Healthcare Conference in Miami, March 8-11, 2026. The presentation is scheduled for March 10, 2026 at 2:20 p.m. ET with CEO Chris Giordano, CMO Stuart Rich, and CBO Douglas Randall.
A live and archived webcast will be available on the company’s investor relations webpage.
Details
News Market Reaction – TENX
On Mar 3, the day this news came out, TENX closed 1.72% below the previous close.
Data tracked by StockTitan Argus for the Mar 3 session.
Key Figures
- Conference dates
- March 8–11, 2026
- 2026 Leerink Partners Global Healthcare Conference window
- Presentation date
- March 10, 2026
- Tenax fireside chat scheduled conference date
- Presentation time
- 2:20 p.m. ET
- Scheduled time for Leerink conference fireside chat
Historical Context
-
Announcement of Guggenheim biotech summit fireside chat with senior management.
-
Phase 3 LEVEL powering update and initiation of global LEVEL-2 trial plans.
-
Participation in two December healthcare investor conferences via fireside chats.
-
Q3 2025 financial results with clinical timelines and patent/cash runway details.
-
Announcement of virtual KOL call discussing TNX-103 Phase 3 program.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHAPEL HILL, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today that the Company will participate in a fireside chat at the 2026 Leerink Partners Global Healthcare Conference, which is taking place from March 8-11, 2026, in Miami, FL.
Details of presentation:
Format: Fireside chat
Participants: Chris Giordano, President & Chief Executive Officer; Stuart Rich, M.D., Chief Medical Officer; Douglas Randall, Chief Business Officer
Date and Time: March 10, 2026, at 2:20 p.m. ET
The live and archived webcast of the presentation will be accessible from the Company’s investor relations webpage.
About Tenax Therapeutics
Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. The Company owns global rights to develop and commercialize levosimendan, which it is developing for the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension globally, for which no product has been approved to date. For more information, visit www.tenaxthera.com. Tenax Therapeutics’ common stock is listed on The Nasdaq Stock Market LLC under the symbol “TENX”.
Contact:
Investor and Media:
Argot Partners
tenax@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.